A Division of Fordham Financial Management, Inc
17 State Street, 22nd Floor
New York, New York 10004
|October 30, 2020|
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|Re:||Inhibikase Therapeutics, Inc. (the “Company”)|
Registration Statement on Form S-1, as amended (the “Registration Statement”)
File No. 333-240036
Ladies and Gentlemen:
On October 27, 2020, ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”), as representative of the underwriters of the offering, joined in the request of the Company that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so as to permit it to become effective on Thursday, October 29, 2020, at 5:00 p.m. (Eastern Time), or as soon thereafter as practicable. The undersigned, on behalf of ThinkEquity, hereby withdraws such request.
|Very truly yours,|
|a division of Fordham Financial Management, Inc.|
|By:||/s/ Eric Lord|
|Title:||Head of Investment Banking|
|cc:||Leslie Marlow, Esq.|
Patrick J. Egan, Esq.